Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, has announced the closing of a private US$152 million Series B financing and initiation of HEROIC, the company’s global Phase 3 clinical study evaluating engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT). The financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX.
Latham & Watkins LLP represented Life Sciences at Goldman Sachs Alternatives in the funding round with a corporate deal team led by Bay Area partner Saad Khanani, with associates Jay Trewn and Camille N’Diaye-Muller. Advice was also provided on data privacy and cybersecurity matters by Bay Area partner Heather Deixler and London partner Calum Docherty, with associates Chad Leiper and Clarence Cheong; on intellectual property matters by San Diego counsel Robert Yeh, with associate Patrick Chew; on life sciences regulatory matters by Paris/Brussels partner Eveline Van Keymeulen and San Diego counsel Amy Speros, with associates Breanna Comunale, Luke Nauth, and Jeanne Fabre; and on tax matters by Bay Area partner Grace Lee, with associate Gregory Conyers.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
